Q1 2024

Filed May 13, 2024 · 10-Q · 43 days after period end · 0001615219-24-000040

Q1 2024 · 10-Q

Revenue—

Net Income

-$1.72M

N/M vs Q1 2023

EPS Diluted

-$3.27

N/M vs Q1 2023

Operating Income-$1,771,615N/M

Operating Cash Flow-$1,353,955N/M

Same quarter

Metric	Q1 2024	Q1 2023	Q1 2022	Q1 2021
Revenue	—	$0.00	$0.00	$1.27M
Net Income	-$1.72M	-$5.34M	-$6.11M	-$1.85M
EPS Diluted	-$3.27	-$2.23	-$3.30	-$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR